Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice N Hartung, S Mollard, D Barbolosi, A Benabdallah, G Chapuisat, G Henry, ... Cancer research 74 (22), 6397-6407, 2014 | 127 | 2014 |
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study L Ehmann, M Zoller, IK Minichmayr, C Scharf, B Maier, MV Schmitt, ... Critical care 21, 1-14, 2017 | 68 | 2017 |
Bayesian data assimilation to support informed decision making in individualized chemotherapy C Maier, N Hartung, J de Wiljes, C Kloft, W Huisinga CPT: pharmacometrics & systems pharmacology 9 (3), 153-164, 2020 | 32 | 2020 |
Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology C Maier, N Hartung, C Kloft, W Huisinga, J de Wiljes CPT: pharmacometrics & systems pharmacology 10 (3), 241-254, 2021 | 28 | 2021 |
Pharmacokinetic/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia J Melin, ZP Parra-Guillen, R Michelet, T Truong, W Huisinga, N Hartung, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), e1729-e1740, 2020 | 28 | 2020 |
Efficient resolution of metastatic tumour growth models by reformulation into integral equations N Hartung | 25 | 2014 |
Predicting cortisol exposure from paediatric hydrocortisone formulation using a semi-mechanistic pharmacokinetic model established in healthy adults J Melin, ZP Parra-Guillen, N Hartung, W Huisinga, RJ Ross, MJ Whitaker, ... Clinical Pharmacokinetics 57, 515-527, 2018 | 23 | 2018 |
A continued learning approach for model‐informed precision dosing: updating models in clinical practice C Maier, J de Wiljes, N Hartung, C Kloft, W Huisinga CPT: pharmacometrics & systems pharmacology 11 (2), 185-198, 2022 | 15 | 2022 |
Physiology-based toxicokinetic modelling of aluminium in rat and man C Hethey, N Hartung, G Wangorsch, K Weisser, W Huisinga Archives of Toxicology 95 (9), 2977-3000, 2021 | 13 | 2021 |
Paracrine and autocrine regulation of gene expression by Wnt-inhibitor Dickkopf in wild-type and mutant hepatocytes N Hartung, U Benary, J Wolf, B Kofahl BMC Systems Biology 11, 1-16, 2017 | 12 | 2017 |
Model description language (MDL): a standard for modeling and simulation MK Smith, SL Moodie, R Bizzotto, E Blaudez, E Borella, L Carrara, ... CPT: pharmacometrics & systems pharmacology 6 (10), 647, 2017 | 12 | 2017 |
Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision N Hartung, CTK Huynh, C Gaudy-Marqueste, A Flavian, N Malissen, ... PLoS One 12 (5), e0176080, 2017 | 12 | 2017 |
The circadian rhythm of corticosteroid‐binding globulin has little impact on cortisol exposure after hydrocortisone dosing J Melin, N Hartung, ZP Parra‐Guillen, MJ Whitaker, RJ Ross, C Kloft Clinical endocrinology 91 (1), 33-40, 2019 | 11 | 2019 |
Parameter non-identifiability of the Gyllenberg–Webb ODE model N Hartung Journal of mathematical biology 68, 41-55, 2014 | 7 | 2014 |
A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs N Hartung, JM Borghardt PLoS Computational Biology 16 (12), e1008466, 2020 | 6 | 2020 |
Time-to-event analysis of paclitaxel-associated peripheral neuropathy in advanced non–small-cell lung cancer highlighting key influential treatment/patient factors FW Ojara, A Henrich, N Frances, W Huisinga, N Hartung, M Joerger, ... Journal of Pharmacology and Experimental Therapeutics 375 (3), 430-438, 2020 | 6 | 2020 |
An efficient implementation of a 3D CeVeFE DDFV scheme on cartesian grids and an application in image processing N Hartung, F Hubert Finite Volumes for Complex Applications VII-Elliptic, Parabolic and …, 2014 | 5 | 2014 |
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients FW Ojara, A Henrich, N Frances, YM Nassar, W Huisinga, N Hartung, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1714-1725, 2023 | 4 | 2023 |
Nonparametric goodness‐of‐fit testing for parametric covariate models in pharmacometric analyses N Hartung, M Wahl, A Rastogi, W Huisinga CPT: Pharmacometrics & Systems Pharmacology 10 (6), 564-576, 2021 | 3 | 2021 |
Stochastic and deterministic models for the metastatic emission process: formalisms and crosslinks C Gomez, N Hartung Cancer Systems Biology: Methods and Protocols, 193-224, 2018 | 3 | 2018 |